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Summary
 
Three lines of transgenic mice have been generated which express human CD25 under the
control of the 722-base pair region located immediately 5
 
9
 
 of the precursor (pre)–B cell–spe-
cific 
 
l
 
5 gene. All three strains express human CD25 in parallel to endogenous 
 
l
 
5 on pre–B
cells, but not on mature B lymphocytes or other blood cell lineages. High expression of human
CD25 on B lineage cells of transgenic mice has allowed the identification of a new
B220
 
1
 
CD19
 
2
 
l
 
5
 
1
 
 precursor of the B220
 
1
 
CD19
 
1
 
l
 
5
 
1
 
 c-kit
 
1
 
 pre-BI cells. Both types of pre-
cursors are clonable on stromal cells in the presence of interleukin-7. The CD19
 
2
 
 precursors
have a sizeable part of their immunoglobulin heavy chain gene loci in germline configuration,
while the CD19
 
1
 
 pre–BI cells are predominantly DJ
 
H
 
 rearranged. The results indicate that ran-
dom integration of the 722-bp 5
 
9
 
 region of the 
 
l
 
5 gene into the mouse genome confers tissue
and differentiation stage–specific expression of a transgene.
 
T
 
wo genes, V
 
preB
 
 and 
 
l
 
5, encode the proteins that to-
gether make up the surrogate L chain (1, 2). Both
genes are specifically expressed in precursor (pre)
 
1
 
–B cells,
but not in immature and mature, surface Ig-positive B cells,
nor in any other cell of mouse or human so far tested (for
review see reference 3). The pre–B cell–specific control of
 
l
 
5 gene expression has been analyzed in some detail (4, 5).
Deletion analysis of a 722-bp 5
 
9
 
 region upstream of the 
 
l
 
5
gene has defined two parts of the upstream region, A
 
l
 
5
 
 and
B
 
l
 
5
 
 (4). A
 
l
 
5
 
, 154 bp directly 5
 
9
 
 of the 
 
l
 
5 gene, functions as
a basal promoter in different types of cells. B
 
l
 
5
 
, 568 bp 5
 
9
 
 of
A
 
l
 
5
 
, acts in concert with A
 
l
 
5
 
 as a suppressor region in non-
pre–B cells, but as an enhancer region on a heterologous
promoter in pre–B cells (4, 5).
Differentially regulated gene expression has allowed to
define, and separate by FACS
 
Ò
 
, B lymphocyte lineage sub-
populations in mouse bone marrow (BM). Hardy et al. (6)
have used the surface antigens heat stable antigen (HSA),
BP-1 and leukosialin (CD43) to separate B220 (CD45R)
 
1
 
pre–B cell populations from immature IgM
 
1
 
 and mature
IgM
 
1
 
/IgD
 
1
 
 B cells. An analysis of the expression of V
 
preB
 
,
 
l
 
5, RAG-1 and RAG-2, TdT, mb-1 and bcl-2, and par-
ticularly the semiquantitation of DJ
 
H
 
, V
 
H
 
DJ
 
H
 
 and V
 
k
 
J
 
k
 
 rear-
ranged Ig genes in populations of these B lineage cells have
allowed Li et al. (7) to propose an order of development of
the subpopulations. The earliest population, called fraction
A, which is CD43
 
1
 
, HSA
 
2
 
, BP-1
 
2
 
 has low, if at all detect-
able, expression of V
 
preB
 
, 
 
l
 
5, RAG-1 and RAG-2, TdT,
and mb-1 and has low quantities of DJ
 
H
 
 rearranged IgH
chain genes while V
 
H(J558)
 
DJ
 
H
 
 and V
 
k
 
J
 
k
 
 rearranged Ig genes
remained below detection limits.
Rolink et al. ordered B220
 
1
 
 B lineage subpopulations in
mouse BM by the analysis of the expression of c-kit, CD25,
and surrogate L chain (8) and by a single cell PCR analysis
of the IgH and L chain loci (9). Rolink et al. (10) then used
the differential expression of B220
 
1
 
 and CD19 to define a
B220
 
1
 
 CD19
 
2
 
 cell population in BM, which could further
be subdivided into three subpopulations, a NK1.1
 
1
 
 precur-
sor population of NK cells, a CD4
 
1
 
 population of un-
known function, and a marker-negative population. These
cell populations are probably largely identical with Hardy’s
fraction A, since they were found to be CD43
 
1
 
, HSA
 
low
 
,
BP-1
 
2
 
. The marker negative CD19
 
2
 
 B220
 
1
 
 cells were sus-
pected to contain some early B lineage progenitors, since
stromal cell/IL-7–reactive cells could be found in low fre-
quencies (10).
In this paper we describe the generation of nine trans-
genic mouse lines in which the gene for the 
 
a
 
 chain of the
human IL-2 receptor (human CD25; hu-CD25) is under
the control of the 722-bp 5
 
9
 
 region of the 
 
l
 
5 gene (5
 
9
 
l
 
5
 
).
In three of the lines the 5
 
9
 
l
 
5
 
 confers lineage and differentia-
tion stage specific–expression of the hu-CD25 transgene in
vivo.
 
Materials and Methods
 
Construction of the Transgene Vector, 5
 
9
 
l
 
5
 
–hu-CD25 and Production
of Transgenic Mice.
 
5
 
9
 
l
 
5
 
 (4) was made by PCR (PCR 1) using the
following primers: 5
 
9
 
 primer: 5
 
9
 
 ACGTCGACTTATATGTCA-
CAGGCTGGCCTTGA 3
 
9
 
, 3
 
9
 
 primer: 5
 
9
 
 CATCAGCAGG-
 
1
 
Abbreviations used in this paper:
 
 BM, bone marrow; HPRT, hypoxanthine
phosphoribosyl transferase; HSA, heat stable antigen; hu-CD25, human
CD25; pre, precursor; RT, reverse transcription.
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TATGAATCCATTGACCCTCAAGTCCAAAGTC 3
 
9
 
. The
hu-CD25 cDNA was made by PCR (PCR 2) using the follow-
ing primers: 5
 
9
 
 primer: 5
 
9
 
 CTTGAGGGTCAATGGATTCAT-
ACCTGCTGATG 3
 
9
 
, 3
 
9
 
 primer: 5
 
9
 
 ACGGATCCCTAGAT-
TGTTCTTCTACTCTTCCT 3
 
9
 
. The 5
 
9
 
l
 
5
 
 3
 
9
 
 primer and the
hu-CD25 5
 
9
 
 primer contain overlapping sequences (underlined)
to facilitate the third PCR. This (PCR 3) was made by using the
5
 
9
 
l
 
5
 
 5
 
9
 
 primer together with the hu-CD25 3
 
9
 
 primer and as tem-
plate use a 1:1 mixture of PCR 1 and PCR 2. The 5
 
9
 
l
 
5
 
 5
 
9
 
 primer
contained a SalI site and the hu-CD25 3
 
9
 
 primer contained a
BamHI site and some extra bases for protection of the respective
restriction site. The PCR product (PCR 3) was cloned into the
vector pSPex23pA as a SalI/BamHI fragment. The pSPex23pA
vector contains human 
 
b
 
-globin exon 2, intron 2, exon 3, and
polyA site (1.6-kb SalI/PstI fragment) from the vector pHSE3
 
9
 
(11) inserted into pSP73 (Promega Corp., Madison, WI) lacking
a BamHI site. The final 5
 
9
 
l
 
5
 
–hu-CD25 vector contained in 5
 
9
 
 to
3
 
9
 
 order the following: 5
 
9
 
l
 
5 as promoter/enhancer, human CD25
cDNA, human b-globin exon 2, intron 2, exon 3, and polyA
site. This 3.2-kb SalI/XhoI fragment was purified and used for
injections.
The purified 3.2-kb SalI/XhoI fragment was microinjected
into (C57Bl/6 3 DBA/2)F2 zygotes as described (12). Transgenic
lines were maintained in pathogen-free conditions and back-
crossed for three generations to C57Bl/6 mice. All experiments
were done with transgenic hemizygotes and their wild-type lit-
termates between 4 and 8 wk of age. For the determination of
transgene copy numbers DNA isolated from tails was analyzed by
slot and Southern blot using the hu-CD25 cDNA and b-actin as
probes.
Antibodies, Flow Cytometric Analysis, and Cell Sorting. The rat
mAb ACK-4 (anti–mouse c-kit; provided by Dr. S. Nishikawa,
Kyoto University, Kyoto, Japan; reference 13) the rat anti–mouse
IgD mAb NIM-R9; (provided by Dr. R. Parkhouse; reference 14)
and the rat anti–mouse CD19 mAb 1D3 (10) were conjugated
with biotin using standard procedures. The following rat mAbs
were purchased from PharMingen (San Diego, CA) PE- and allo-
phycocyanin-conjugated RA-6B2 (CD45R, B220), biotinylated
7D4 (anti–mouse CD25, TAC), PE-conjugated RM4-5 (anti–
mouse CD4), PE-conjugated PK186 (anti–mouse NK1.1), and
FITC- and PE-conjugated M-A251 (anti–human CD25). FITC-
conjugated goat anti–mouse IgM (m chain specific) was obtained
from Southern Biotechnology Associates (Birmingham, AL).
Single cell suspensions from BM were prepared by flushing out
cells from femurs with either ice-cold staining buffer (PBS con-
taining 2% FCS and 0.1% NaN3) or tissue culture medium
(IMDM, 2% FCS). Cells were incubated with a combination of
FITC-, PE-, biotin- or allophycocyanin-conjugated antibodies in
staining buffer, washed with staining buffer, incubated for 15 min
with PE-streptavidin (Southern Biotechnology Associates) to re-
veal the biotin reagent, and finally washed with staining buffer.
Cells were analyzed on a FACScanÒ instrument (Becton Dickin-
son, Mountain View, CA). In double staining experiments pro-
pidium iodide was included in the staining buffer (1 mg/ml) to
gate out dead cells. Cells present in the extended lymphocyte gate
(low side scatter) were gated. Cell sorting was performed on a
FACStar PlusÒ instrument. For the sorting of rare populations
such as the B2201CD192 fractions in BM, a two step sorting
protocol was used to obtain maximum purity. During the first
sorting, the instrument was set on enrichment mode. The purity
after the first round was generally .85%. After the second sorting
of the enriched cells, the purity was generally .96% when reana-
lyzed with the instrument settings used for the sort.
Pre–B Cell Culture System. Pre-B cell lines were established
from fetal livers of individual day 17 embryos from pregnant trans-
genic mice. The pre-B cell lines and clones were cultivated as de-
scribed (15). In brief, pre–B cells were cultured on a semiconflu-
ent layer of g-irradiated (30 Gy) ST-2 stromal cells (16) in IMDM
containing 100 mg/ml kanamycin, 5 3 1025 M 2-mercaptoetha-
nol, 2% heat-inactivated FCS (GIBCO BRL, Gaithersburg, MD)
and 100 U/ml IL-7. Culture supernatant of J558L cells trans-
fected with the murine IL-7 cDNA in the BMG neo vector was
used as a source of IL-7 (17). When stable pre–B cell lines were
established, the cells were transduced with a retrovirus containing
the mouse bcl-2 gene (a gift from Dr. M. Busslinger, Research
Institute of Molecular Pathology, Vienna, Austria) and transduced
cells were selected with 3 mg/ml puromycin on puromycin-resis-
tant ST-2 cells. For the induction of differentiation of bcl-2 trans-
fected pre–B cells, cells were harvested, washed three times in
medium without IL-7, and cultured on a semi-confluent layer of
g-irradiated ST-2 stromal cells in medium without IL-7.
Limiting Dilution Analysis of Pre–B Cells Growth. Cell suspen-
sions from FACSÒ sorted cells were diluted by serial twofold dilu-
tions in medium with IL-7 and were plated on a semi-confluent
layer of g-irradiated (30 Gy) ST-2 cells in 96-well flat-bottom plates.
Cultures were scored on day 7 for pre–B cell colonies containing
.50 cells, using an inverted microscope. On several occasions,
the contents of individual wells with lymphoid colonies were re-
moved and analyzed for B220 and CD19 expression by FACSÒ.
In all cases, the cells uniformly expressed B220 and CD19.
Northern Blot Analysis. Total cellular RNA was prepared us-
ing RNAzol B (Biotecx Laboratories, Inc., Houston, TX) accord-
ing to the manufacturer’s recommendations and analyzed as de-
scribed (18). The complete cDNA of the hu-CD25 was used as a
probe for the detection of hu-CD25 RNA.
Reverse Transcription–PCR. RNA extraction, cDNA synthe-
sis, and reverse transcription (RT)-PCR was done exactly as de-
scribed (19). The following primer-pairs were used: hypoxan-
thine phosphoribosyl transferase (HPRT): 59 GCTGGTGAAAAG
GACCTCT 39, 59 CACAGGACTAGAACACCTGC 39; l5: 59
GAGATCTAGACTGCAAGTGAGGCTAGAG 39, 59 CTTGG-
GCTGACCTAGGATTG 39; hu-CD25/b-globin: 5 AGAC-
CAGTCAGTTTCCAGGTGAA 39, 59 AAGCGAGCTTAGT-
GATACTTGTG 39. All PCRs were carried out with 1 cycle
948C for 40 s, followed by 30 cycles at 948C for 20 s, 558C for 15 s,
and 728C for 60 s. The probes specific for the HPRT, l5, and
hu-CD25 genes were generated by cloning PCR fragments into
pBluescript and were used for PCR–Southern blot analysis.
PCR Analysis of IgH Gene Rearrangements. DJH rearrangements of
the H chain locus were amplified and detected using PCR as out-
lined in Fig. 4. Two forward primers binding immediately up-
stream of DFL/DSP elements or the DQ52 element, respectively,
were used in a mixture (DFS and DQ52 as described in reference
20) together with one reverse primer binding downstream of JH4
(JH4A in reference 16). In germline configuration, the DQ52 and
JH4A primers will amplify the 2.15-kb germline fragment. DJH1,
DJH2, DJH3, and DJH4 rearrangements involving either DFL, DSP,
or DQ52 elements will be detected by the emergence of bands of
1.46, 1.15, 0.73, and 0.20 kb, respectively.
Cells were sorted directly into 100 ml PBS containing 0.5%
Tween 20 and proteinase K (0.2 mg/ml; Boehringer Mannheim
GmbH, Mannheim, FRG) and incubated at 558C for 2 h. The
preparations were boiled and DNA was precipitated in ethanol
with glycogen as the carrier. The DNA pellet was dissolved in
Tris-HCl, pH 8.3. The DNA equivalent of 50 sorted cells was
subsequently used for PCR amplification. The amplification pro-655 Mårtensson et al.
tocol was 35 cycles of 20 s at 948C, 30 s at 658C, and 2 min at
728C. An oligonucleotide specific for the JH4 region (59 AG-
GAACCTCAGTCACCGTC 39) was used for PCR–Southern
blot analysis.
Results
The 722-bp region of the l5 upstream regulatory region
(4) was inserted upstream of the hu-CD25 cDNA (21) and
introduced as a transgene into the germline of mice. Cells
from BM and spleen of nine founder strains carrying the
transgene were analyzed by FACSÒ for hu-CD25 expres-
sion. Three of the nine strains were found to express sur-
face hu-CD25. As determined by Southern and slot blot
analyses (Table 1), transgene copy numbers varied between
10 and 30 in expressing and between 4 and 400 in nonex-
pressing strains. This indicates that expression of hu-CD25
was most likely influenced by integration sites.
The analysis of the cellularity as well as the staining of
the different B cell differentiation stages in BM and spleen
(as described in detail previously in reference 15) revealed
that in none of the transgenic lines was lymphocyte devel-
opment disturbed by any means (Table 2) in agreement
with other studies using hu-CD25 as transgene (22). All
three founder strains expressing the transgene showed simi-
lar staining patterns in BM (as shown in Fig. 1 A for the
founder 82). Several levels (high, intermediate, and low) of
hu-CD25 expression were detected in B lineage cells in the
BM, while spleen and thymus cells were practically nega-
tive (Fig. 1 A). The z0.5% of spleen cells which expressed
very low levels of hu-CD25 were found to be IgM1IgD2
immature B cells (data not shown). Most hu-CD25 positive
BM cells expressed the B cell markers CD19 and CD45R
(B220; Fig. 1 A, and data not shown). RT-PCR analysis of
BM, spleen, liver, muscle, and heart readily detected hu-
CD25 RNA in the BM and low levels in the spleen but no
signal was found in the nonlymphoid samples, while the
HPRT control primers detected HPRT RNA in all organs
(Fig. 1 B). Thus, the 59l5 control region contains lineage–
and differentiation stage–specific promoter/enhancer activity.
Three-color FACSÒ analysis of BM cells was performed
in order to define the stages at which the transgene was ex-
pressed and to analyze if this correlated with expression of
the endogenous l5 gene. Fig. 2 shows the analyses of the
expressor strains 82 and 83 in which cells expressing CD19
and a second marker were gated and the levels of hu-CD25
analyzed. Strain 73 showed virtually identical expression
levels of transgenic hu-CD25 to strain 82 (data not shown).
Strain 83 displayed z5–10-fold lower levels when com-
pared with the other two strains. While strains 82 and 73
both contained about 30 transgene copies, strain 83 con-
tained about 10 copies. In BM cells from line 82 and 73, high
levels of hu-CD25 were found on c-kit1 pre–BI cells, in-
termediate levels were found on mouse CD251 large pre–
BII cells, low expression on mouse CD251 small pre–BII
cells, while very little or no expression was detected on im-
mature (IgM1IgD2) and mature (IgM1IgD1) B lympho-
cytes. Expression of hu-CD25 protein correlated with trans-
genic RNA steady state levels were determined by RT-PCR
analysis; high levels of transgenic RNA were detected in
pre–BI cells, intermediate and low levels in large and small
pre–BII cells, respectively, and very little or no transgenic
RNA was detected in immature and mature B cells (not
shown). Parallel analysis of endogenous l5 gene transcript
levels demonstrated that l5 was expressed in a similar fash-
ion, in agreement with previous analyses (19), with the ex-
ception that slightly lower relative amounts were detected
in the later differentiation stages as compared to transgenic
hu-CD25 RNA. Thus, in general, the expression of hu-
CD25 protein and RNA correlated with that of endoge-
nous l5. Both the endogenous l5 gene and the 59l5-con-
trolled transgene generate transcripts which are expressed
in pre–BI cells and begin to be downregulated as these cells
differentiate into pre–BII cells.
The developmental control of transgenic hu-CD25 ex-
pression in B lymphocyte development was further ana-
lyzed in differentiating pre–B cells in vitro. c-kit1 pre–BI
cells can be expanded in vitro on stromal cells in the pres-
Table 1. Summary of Transgenic Founder Lines
TG strain No. Copy numbers
hu-CD25
expression
54 4 2
15 12 2
50 12 2
83 12 1
73 24 1
82 24 1
52 24 2
35 100 2
57 400 2
Table 2. Phenotypic Characterization of BM Cells in 59l5
hu-CD25 Transgenic Mice and Normal Littermates
Phenotypic markers
tg1 tg2
(percentage of
nucleated BM cells)
B2201CD192 3.6 4.0
CD191 c-kit1 3.4 3.3
CD191 mCD251 large 5.2 4.9
CD191 mCD251 small 20.7 22.3
IgM1IgD2 10.9 9.7
IgM1IgD1 6.1 5.3
The data are average values of three 6-wk-old mice each. BM cellular-
ity was normal in all mice (1.2–1.5 3 107 cells/femur).656 A Transgenic Marker for Mouse B Lymphoid Precursors
ence of IL-7 (15). Therefore, c-kit1 pre–BI cells from fetal
liver of transgenic mice were cultured on ST-2 stromal cells
in the presence of IL-7 and transduced with a retrovirus
encoding the bcl-2 cDNA to inhibit apoptosis after re-
moval of IL-7. As shown in Fig. 3 A, the cells in culture
expressed CD19, l5 protein (as detected by the LM34 an-
tibody; reference 23) and high levels of hu-CD25, but no
detectable IgM on the cell surface. Withdrawal of IL-7 and
analysis 1, 2, and 3 d thereafter demonstrated that the level
of CD19 expression remained constant while the surface
expression of l5 and hu-CD25 decreased with time. In ad-
dition, z10% of the cells started to express IgM on the cell
surface at day 3 of differentiation. Furthermore, Northern
blot analysis of these differentiating cells showed that the
RNA steady state levels of hu-CD25 and l5 decreased
with time of differentiation (Fig. 3 B). Disappearance of
hu-CD25 paralleled the disappearance of l5 RNA (Fig. 3
B). Again, these results indicate that the hu-CD25 trans-
gene, like endogenous l5, is expressed in pre–BI cells. Ex-
pression of the endogenous l5 and hu-CD25 transgene is
downregulated as these pre–BI cells differentiate in vitro to
sIgM1 immature B cells.
Analysis of BM cells for hu-CD25 expression detected a
population of cells which did not express the B lineage
marker CD19, but did express intermediate levels of hu-
CD25 (Figs. 1 and 4). This population was found to be
B220 positive (Fig. 4), and therefore, belongs to the mix-
ture of B2201CD192 BM cells recently analyzed to be
composed of NK1.11 precursors to NK, CD41, and marker-
negative cells (10). B cell precursor activity was found only
in the marker-negative subpopulation. This marker-nega-
Figure 1. 59l5 is active in BM but not in spleen, thymus, heart, muscle,
or liver. 59l5 hu-CD25: 59l5 inserted upstream of the cDNA encoding
human IL-2–R (hu-CD25; reference 21) followed by exon 2, intron 2,
exon 3 (solid boxes), and polyA site (hatched box) from human b-globin
(11). The 59l5 hu-CD25 was used to establish transgenic mice. (A) BM,
spleen, and thymus cells were analyzed by FACSÒ using antibodies de-
tecting mouse CD19 or CD4 and hu-CD25. Data from nontransgenic
(tg2) and transgenic (tg1) littermates from founder 82 are shown. (B) Total
RNA from heart, muscle, liver, spleen, and BM was isolated and analyzed
for expression of hu-CD25 and HPRT by RT-PCR analysis. Arrows de-
note the 185 and 220-bp fragments of hu-CD25 or HPRT, respectively.
Figure 2. Expression of the transgene correlates with the stage of dif-
ferentiation of B lineage cells in the BM. Three-color FACSÒ analysis of
BM cells from founder 82 and 83. Cells were gated for CD191 lympho-
cytes coexpressing the markers c-kit for pre–BI cells, murine CD25 for
pre–BII cells (further subdivided into large and small pre–BII cells accord-
ing to forward scatter characteristics), and IgM and IgD for immature and
mature B cells. The level of hu-CD25 was then determined on gated
cells.657 Mårtensson et al.
tive subpopulation amounts to approximately one-third of
all B2201CD192 cells, i.e., 1–2% of all BM nucleated cells
(10). In the 59l5–hu-CD25 transgenic mice the B2201
CD192 hu-CD251 cells did not express NK1.1, or CD4
(Fig. 4), and are therefore found within the marker-negative
subpopulation. This marker-negative hu-CD251 subpopu-
lation comprises 10–15% of all B2201CD192NK1.12 CD42
cells (Fig. 4), i.e., 0.1–0.3% of all BM cells.
The marker-negative subpopulation was sorted into hu-
CD251 and hu-CD252 cells and analyzed for other mark-
ers, in particular for the expression of endogenous l5. RT-
PCR analysis shown in Fig. 5 A revealed that these cells,
like CD191 pre–BI cells coexpressed hu-CD25 and endog-
enous l5, whereas hu-CD252 sorted cells from the same
B2201CD192 population contained no detectable l5 or
hu-CD25 message. The B2201CD191 hu-CD251 cells
also expressed VpreB, sterile m H chain, RAG-1, RAG-2,
and B29 transcripts (data not shown). PCR analysis of the
H chain gene loci of the B2201CD192 hu-CD251 cells re-
vealed that a sizeable fraction of all loci were still in germ-
line configuration while the rest of these loci were DJH re-
arranged (Fig. 5 B, lane 3). VHDJH rearranged loci could not
Figure 3. Downregulation of transgene expression upon differentiation of in vitro cultivated pre–B cell lines. Pre–B cell lines were cultivated in the
presence of IL-7 on ST-2 stromal cells as described (15), and differentiation was induced by withdrawal of IL-7. (A) After 0, 1, 2, and 3 d in the absence
of IL-7, the cells were stained with antibodies specific for CD19, l5 (as detected by the mAb LM34; reference 23), hu-CD25, and IgM, and analyzed by
FACSÒ. Fluorescence intensities are displayed (solid histograms) and the fluorescence intensity of an irrelevant antibody is overlaid (open histograms). (B) Af-
ter 0, 1, 2, 3, and 5 d in the absence of IL-7, the cells were harvested and RNA was prepared and subjected to Northern blot analysis using l5, hu-CD25,
and b-actin specific probes.
Figure 4. FACSÒ sorting pro-
cedure and reanalyzed data of
transgenic BM cells analyzed for
expression of B220, CD19, CD4,
NK1.1, and hu-CD25. BM cells
depleted of IgM1 cells (see Ma-
terials and Methods) were stained
with anti–B220-APC, anti–CD19-
PE, anti–CD4-PE, anti–NK1.1-
PE, and anti–hu-CD25–FITC.
B2201CD192CD42NK1.12 cells
(gate R1) were gated and ana-
lyzed for hu-CD25 expression.
Hu-CD25 positive (gate R3) and
negative cells (gate R2) among
the B2201CD192 CD42NK1.12
population were sorted sepa-
rately and the obtained fractions
were reanalyzed after sorting.658 A Transgenic Marker for Mouse B Lymphoid Precursors
be detected (data not shown). In CD191 c-kit1 pre–BI
cells (lane 2) the H chain gene loci were found to be mostly
DJH rearranged in agreement with previous analyses (9).
We conclude from these analyses that the B2201CD192
NK1.12CD42 hu-CD251 cells contain early B lineage pre-
cursors. Since they have a considerable fraction of their
H chain loci in germline configuration they might be pre-
cursors of the CD191 pre–BI cells. The B2201CD192 hu-
CD252 l52 BM cells might not belong to the B lineage.
These conclusions were further supported by an analysis of
the proliferation and differentiation potential of these early
B2201CD192 cell populations. Limiting dilution analyses
on stromal cells in the presence of IL-7 (15) showed that
the CD191 hu-CD25high pre–BI cells (1 in 12) as well as
the B2201CD192 hu-CD251 B lineage precursors (1 in
15) contained a similarly high frequency of clonable cells
(Fig. 5 C). This frequency of clonable cells in the B2201
CD192NK1.12CD42 hu-CD251 cell population is, there-
fore, z10-fold higher than the frequency found previously
by Rolink et al. (10) in the total B2201CD192NK1.12
CD42 population. We therefore conclude that the hu-
CD25 reporter transgene is preferentially expressed in early
clonable B lineage precursors before the expression of CD19.
It should be noted that in comparison to the pre–BI–
derived colonies, the B2201CD192 hu-CD251–derived col-
onies were larger in size and contained more cells. After 7 d in
tissue culture, the CD192 hu-CD251 precursors became
CD19 positive and the cells could be induced to differentiate
to IgM1 immature B cells upon removal of IL-7 from the cul-
tures (data not shown). The B2201CD192 hu-CD252 cells
showed 20–30-fold lower frequency of clonable lymphoid
cells in the above mentioned culture system (Fig. 5 C).
Collectively, these results show that the high expression
of the transgenic hu-CD25 on the surface of BM cells has
Figure 5. Characterization of the B2201CD192 negative cell population in BM of mice expressing the hu-CD25 transgene under the control of the
59l5. (A) Expression of hu-CD25, endogenous l5, and HPRT in sorted cell populations. BM cells were sorted by FACSÒ after triple labeling for B220,
CD19, and hu-CD25, or double labeling for CD19 and c-kit, respectively. Fivefold dilutions of cDNA from sorted cells were subjected to PCR ampli-
fication of hu-CD25, l5, and HPRT genes and PCR products detected by Southern blotting with specific probes. (B) PCR-mediated analysis of the re-
arrangement status of the IgH locus in sorted cell populations. DNA of sorted cells was subjected to PCR amplification as outlined in the top of the fig-
ure. After electrophoresis and Southern blotting, the PCR products were detected by hybridization with a JH4-specific oligonucleotide. Sorted cell
populations are in lane 1, B2202 c-kithigh; lane 2, CD191 c-kit1, and lane 3, B2201CD192 hu-CD251. (C) Limiting dilution analysis of FACSÒ sorted
B2201 cells from BM on ST-2 stromal cells in the presence of IL-7. Growth of pre–B cell colonies consisting of .50 cells was scored on day 7 of culture.
24 replicate cultures for each cell number were initiated. According to Poisson distribution, one precursor is present in the cell suspension when 37% of
the cultures do not show colonies.659 Mårtensson et al.
allowed the isolation and characterization of an early B lin-
eage cell population that is likely to be precursors of pre–BI
cells.
Discussion
The three transgenic strains of mice presented here carry
the cDNA of the a chain of the human IL-2 receptor
(CD25) under the control of the 722-bp 59 regulatory re-
gion of the l5 gene. The 59l5 regulatory region, consisting
of Al5 and Bl5, conveys lineage and differentiation stage
specificity to the expression of the transgenic reporter gene,
hu-CD25. This expression pattern in vivo confirms and ex-
tends previous results from the analysis of various cell lines
representing different stages of B cell development (4, 5).
In the previous experiments, however, a heterologous en-
hancer was used in the reporter gene constructs in addition
to the 59l5 regulatory region to obtain measurable levels of
reporter gene expression. We show here that the short
stretch of the 722-bp 59 regulatory region contains the es-
sential cis-acting regulatory elements for lineage and differ-
entiation stage specific expression. Our experiments do not
provide any evidence for the need of additional enhancer
elements for this specific expression. It will now be possible to
study the function of the 59l5 regulatory region in greater
detail.
It appears that the copy number of transgenes inserted
into the mouse genome is not important for the specificity
of expression. Furthermore, insertion of the transgene at
different sites in the genome only determines the level, and
not the specificity, of expression. These results indicate that
it will be possible to express other transgenes in a pre–B
cell–specific fashion without inserting them at the l5 locus
by homologous recombination.
Lineage- and tissue-specific expression conferred by a
short 59 region has also been reported for other genes.
Among the earliest genes analyzed in this context was the
rat insulin gene in which the 700-bp 59 region was shown
to drive the expression of the simian virus 40 large T anti-
gen in b cells of the pancreas, and the transgenic mice de-
veloped b cell tumors (24). The insulin 59 region has sub-
sequently been used to direct b cell–specific expression of
many genes. The insulin enhancer within these 700 bp, in
the context of its own promoter, confers gene expression
only in b cells, while in the presence of a heterologous
promoter, the same enhancer is not as restricted and allows
expression in the brain also (25). Another example is the
620-bp proximal promoter of the lck gene. It was shown to
allow expression in thymocytes, but not in peripheral T cells,
in agreement with lck proximal promoter driven transcrip-
tion in T cell development (26), though the defined differ-
entiation stages in the thymus were not analyzed.
Perhaps the most widely used system expressing a trans-
gene within the lymphoid system takes advantage of the
well characterized IgH intron enhancer (Em) (27–29), ei-
ther in combination with an Ig promoter or with a heterol-
ogous promoter. Such combinations allow expression not
only in B, but also in T lymphocytes. Since Em seems to
overrule the specificity of even a locus control region (30),
it appears not suited for transgene expression if a more nar-
row window of expression is preferred.
In general, expression of the hu-CD25 transgene paral-
leled that of the endogenous l5 gene. In c-kit1 pre–BI
cells and in large pre–BII cells, l5 and transgene expression
was highest. In these differentiation stages, using currently
available reagents, l5 protein is detectable either in the cy-
toplasm (8) or on the cell surface (31). Small differences can
be seen in the small pre–BII/immature B cell compart-
ments. The data shown in Fig. 2 indicate that the hu-
CD25 is expressed as protein in small pre–BII cells, and at
even lower levels in immature B cells in two of the three
founder lines. Endogenous l5 protein was not detectable at
the later differentiation stages and l5 mRNA was reduced
about 20–30-fold when compared to pre–BI cells (refer-
ence 19 and unpublished observation). The hu-CD25 trans-
gene contains human b-globin sequences which might pro-
long mRNA half-life as compared to endogenous l5 and,
hence, protein synthesis. In addition, hu-CD25 protein might
be more resistant than l5 to degradation which again could
contribute to prolonged expression of hu-CD25 in differ-
entiating B lineage cells in BM.
The easily detectable expression of the transgenic hu-
CD25 protein on the surface of cells has permitted the
identification of a CD192B2201 hu-CD251 cell popula-
tion in the BM that are NK1.12 and CD42. These novel
cells were also found to express endogenous l5, and as a
population, to contain cells that have started to rearrange
their IgH gene loci. A high proportion of these CD192
B2201 hu-CD251 cells are clonable on stromal cells in the
presence of IL-7. In fact, the frequency of clonable cells is
as high as in the CD191B2201 hu-CD25high c-kit1 pre–BI
cell population. Given that the plating efficiency in these
cultures is not 100% (32), the actual frequencies may be
even higher. At present it can not be completely ruled out,
however, that the CD192B2201 hu-CD251 cell popula-
tion, which represents about 5% of all CD192B2201 in the
BM of transgenic mice, is nevertheless heterogeneous. The
finding that the CD192 hu-CD251 population contains
much more of the IgH loci in germline configuration ar-
gues that the CD192 hu-CD251 cells are the precursors of
the CD191 pre–BI cells. Our results agree with previous
analyses of the configuration of IgH and L chain loci un-
dertaken by Li et al. (7) for Hardy’s fraction A of mouse
BM, and suggest that the DJH rearranged IgH chain loci
found by these authors are contributed by B2201CD192
NK1.12CD42 cells, now further marked by the hu-CD25
reporter transgene.
To date, it is clear that cells expressing CD19 are com-
mitted to the B cell lineage. However, stages of hemopoie-
sis before B cell commitment are poorly understood. The
hu-CD25 transgenic mice described in this paper may help
to further characterize these early stages of B lineage devel-
opment and commitment. In addition, they may help fur-
ther in elucidating the early arrests in B cell development
observed in mutant mice defective for, e.g., E2A (33, 34)
or EBF (35).660 A Transgenic Marker for Mouse B Lymphoid Precursors
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